What is HC Wainwright’s Forecast for Verastem Q1 Earnings?

Verastem, Inc. (NASDAQ:VSTM) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Verastem in a research report issued to clients and investors on Monday, March 24th. HC Wainwright analyst S. Lee forecasts that the biopharmaceutical company will post earnings per share of ($0.67) for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Verastem’s current full-year earnings is ($3.02) per share. HC Wainwright also issued estimates for Verastem’s Q2 2025 earnings at ($0.74) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.62) EPS, FY2026 earnings at ($1.10) EPS and FY2027 earnings at ($0.33) EPS.

A number of other research analysts also recently commented on VSTM. StockNews.com upgraded shares of Verastem from a “sell” rating to a “hold” rating in a research note on Monday, March 24th. Guggenheim increased their price target on shares of Verastem from $13.00 to $14.00 and gave the stock a “buy” rating in a research report on Monday, March 24th. Mizuho boosted their price objective on Verastem from $7.00 to $9.00 and gave the company an “outperform” rating in a report on Thursday, December 19th. B. Riley increased their target price on Verastem from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Friday, January 31st. Finally, Royal Bank of Canada lowered their price target on Verastem from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Friday, March 21st. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, Verastem currently has an average rating of “Moderate Buy” and an average target price of $13.88.

Verastem Stock Down 8.0 %

VSTM stock opened at $6.19 on Thursday. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 2.77. The firm has a 50 day simple moving average of $6.14 and a 200-day simple moving average of $4.76. The company has a market capitalization of $318.70 million, a P/E ratio of -1.94 and a beta of 0.60. Verastem has a twelve month low of $2.10 and a twelve month high of $13.52.

Verastem (NASDAQ:VSTM) last issued its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.57).

Institutional Investors Weigh In On Verastem

A number of hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC grew its holdings in Verastem by 51.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,997 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 1,698 shares in the last quarter. FMR LLC bought a new position in shares of Verastem in the third quarter worth $41,000. JPMorgan Chase & Co. increased its holdings in shares of Verastem by 55.4% during the third quarter. JPMorgan Chase & Co. now owns 16,878 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 6,016 shares during the period. ProShare Advisors LLC bought a new stake in shares of Verastem during the fourth quarter valued at about $56,000. Finally, Voya Investment Management LLC acquired a new stake in Verastem in the fourth quarter worth about $59,000. Institutional investors own 88.37% of the company’s stock.

Insider Buying and Selling

In other Verastem news, CEO Dan Paterson sold 8,568 shares of the business’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $5.24, for a total transaction of $44,896.32. Following the completion of the transaction, the chief executive officer now directly owns 347,581 shares of the company’s stock, valued at $1,821,324.44. The trade was a 2.41 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 9,960 shares of company stock worth $53,498 in the last three months. 2.20% of the stock is owned by insiders.

Verastem Company Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.